Previous 10 | Next 10 |
home / stock / myco:cc / myco:cc news
VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatm...
DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental ...
Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2023. October 2023 Operating Statistics Trading volume of CSE-listed securities totaled 915 million shares; Trading value of CSE-...
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has filed a shelf prospectus supplement to...
VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment prot...
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has released a fourth-quarter 2023 company...
VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment pro...
--News Direct-- Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector. Bartch explains that Mydecine focuses on developing "second genera...
Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has completed its admission to the Access ...
VANCOUVER, British Columbia, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA) , a biotechnology company engineering the next wave of innovative medications and treatment...
News, Short Squeeze, Breakout and More Instantly...
MYDECINE INNOVATIONS GROUP INC. Company Name:
MYCO:CC Stock Symbol:
AQNC Market:
(TheNewswire) VANCOUVER, British Columbia – TheNewswire - May 2, 2024 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has requested a temporary Management Cease Trade Orde...
(TheNewswire) VANCOUVER, British Columbia, May 2, 2024 ( The N ewswire ) — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) announces that it has received a temporary Management Cease Trade O...
(TheNewswire) VANCOUVER, BC – TheNewswire - (May 1, 2024) Mydecine Innovations Group Inc . (CSE: MYCO) (FSE: 0NFA), (OTC: MYCOF) (AQSE: MYIG) (the “ Company ” or “ Mydecine ”) announced that it has entered into certain restr...